PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2026The Lancet2 citations

Efficacy and safety of a bodyweight–adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials

View Full Paper
SHStephen L HauserGGGavin GiovannoniXMXavier Montalban

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hauser et al. (2026) studied this question.

synapsesocial.com/papers/6a19ae76e2fc26910d02b6f5https://doi.org/10.1016/s0140-6736(26)00147-9
Ask AI
Helpful
Bookmark
Share
View Full Paper